Elastosis perforans serpiginosa (EPS) is a rare complication of chronic therapy with a high-dose of D-penicillamine (1 g daily for more than 5 years), characterized by the elimination of abnormal elastic fibers from the upper dermis through the epidermis. D-penicillamine (DPA) is a heavy metal chelator primarily used for disorders such as cystinuria and Wilson disease. This therapy can lead to induction of EPS through a still unknown mechanism. We report the follow-up of aD-penicillamine-induced EPS in patient with Wilson disease, which prompted us to switch the therapy with trientine (another metal chelator). After 14 years the cutaneous lesions are still visible; therefore, we conclude that the DPAinduced cutaneous damage is irreversible.
In 1992, a 32-year-old man was referred to our Department of Dermatology because of a 4-year history of annular and serpinginous lesions located on his neck, armpits and buttocks, 5-6 em in diameter, with hyperkeratotic reddish-brown papules, leaving a central area of atrophic skin. General examination revealed only dysphonia of new insurgence. He had been diagnosed with Wilson's disease at the age of 14 on the basis of hepatic manifestations and he had been treated with DPA (900 mg/die) for 18 years. Blood count, biochemistry (except slight increase of rate liver function), autoantibodies and immunoglobulins screenings were in the normal range. Ceruloplasmin, urine copper and serum copper levels were consistent with Wilson's disease, in the decopper state. Histological evaluations revealed focal acanthosis and parakeratosis of epidermis with transepidermal elimination of elastolitic material, an inflammatory infiltrate and multinucleate giant cells phagocytizing abnormal elastic fibers in the dermis ( Fig. 1 a and b ). Elastin van Gieson stain showed abnormal elastic fibers with a lumpy-bumpy or bramble-bush appearance, which are typically seen in elastosis due to penicillamine. Thus, a final diagnosis of D-penicillamine-induced Elastosis perforans serpiginosa was made and he was changed to trientine dihydrochloride 1800 mg/ die. A progressive improvement of the inflammatory pattern of the cutaneous lesions was observed during the following years, but after an 18-year follow-up papulo-serpiginous lesions are still present on his neck, armpits and buttocks.
Elastosis perforans serpiginosa (EPS) is a reactive perforating dermatosis characterized by elimination of abnormal elastic fibers from the upper dermis through the epidermis, clinically resulting in umbelicated papules arranged in a serpiginous pattern. (1) It is often associated with an underlying systemic disorder such as connective tissue alteration, but its exact incidence is still unknown (2) . In few cases, it occurs as a side effect of treatment with O-penicillamine (OPA), after many years of high-dose therapy. O-penicillamine is a copper chelator used with success for the treatment of Wilson disease, and other pathologies such as cystinuria, rheumatoid arthritis, scleroderma and primitive biliary cirrhosis. Cutaneous adverse reactions are very commons (25-50%), but the elastic fiber's alterations are very rare (l,3). Doses of 1 g daily for more than 5 years, have been suggested as the minimal dose/duration prior to displaying these histological changes, not only in the cutis, but also in different organs, such as lung, pharynx, aorta, joint capsules and adventitia of the viscera. Pharyngeal and tongue thickness with dysphonia and alterations of cough reflex are the main reported symptoms (1). The first case ofOPA-induced EPS in a patient treated for Wilson's disease was described in 1972 (5) . The exact patho-mechanism is still unknown; probably, at higher doses, OPA may interfere with elastin cross-linking through inhibition of the enzyme Iysyl oxidase, or by formation of complexes with the crosslinked precursors, impairing a normal maturation of elastic fibers (6) .
Treatment of EPS is difficult: topical tretinoin, topical or intralesional corticosteroids, cryotherapy, curettage and laser have been tried with inconsistent results. The first step is OPA discontinuation. Effective alternative therapies for Wilson's disease include zinc, which reduces intestinal absorption of copper, or trientine dihydrochloride, an alternative chelator; with these drugs no evidence of elastic fiber damage has been reported. (5) In our case the clinical and histological patterns led to a diagnosis of EPS induced by OPA and the patient therefore underwent therapy with trientine with a slight improvement of inflammatory pattern. The presence of pharyngeal symptoms, led to disruption of elastic fiber, and could be considered as an initial sign of systemic damage induced by OPA. The cutaneous manifestations that could represent those first and more evident, could lead to a precocious diagnosis of this condition. The clinicians must be aware of this possibility; in fact, the change of therapy avoids damage progression.
We report this case to renew attention on this rare condition. Moreover, we want to stress the concept that the histological elastophagic damage is chronic and irreversible, as confirmed by our case. In literature no other cases with a similar follow-up have been reported.
